Clinical trial

Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer

NCT01824342

Study summary

ClinicalTrials.gov

Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

BIOLOGICAL · Unmapped registry intervention Denosumab Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2011-01-01

PhasePHASE3

Conditions

Castrate-resistant Prostate Cancerunresolved

Interventions

DenosumabBIOLOGICAL

Sponsors & collaborators

Amgenlead sponsor

Mapped research locations

PragueCzechia2 SheffieldUnited Kingdom1 Hradec KrálovéCzechia1 SuttonUnited Kingdom1 NewcastleUnited Kingdom1 TáborCzechia1 NorthwoodUnited Kingdom1 PelhřimovCzechia1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01824342 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.